Manuscript version: Author’s Accepted Manuscript
The version presented in WRAP is the author’s accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:
http://wrap.warwick.ac.uk/126177

How to cite:
Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher’s statement:
Please refer to the repository item page, publisher’s statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# The Heart Failure with Preserved Ejection Fraction (HFPpEF) Pathophysiology, observational Study (IDENTIFY-HF): does increased arterial stiffness associate with HFPpEF, in addition to ageing and vascular effects of co-morbidities? - rationale and design.

<table>
<thead>
<tr>
<th>Journal:</th>
<th>BMJ Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bmjopen-2018-027984.R1</td>
</tr>
<tr>
<td>Article Type</td>
<td>Protocol</td>
</tr>
<tr>
<td>Date Submitted by the Author</td>
<td>20-Aug-2019</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Ali, Danish; University Hospital Coventry, University of Warwick Warwick Medical School, Callan, Nualla; (a) University Hospitals Coventry and Warwickshire NHS Trust Ennis, Stuart; University Hospitals Coventry and Warwickshire NHS Trust, Cardiac Rehabilitation; Cardiff Metropolitan University, Cardiff Centre for Exercise &amp; Health Powell, Richard; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation McGuire, Scott; Department of Cardiac Rehabilitation, Centre for Exercise and Health, University Hospital, Coventry, UK McGregor, Gordon; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation Weickert, Martin; University Hospitals Coventry &amp; Warwickshire NHS Trust, University of Warwick Medical School, Division of Translational and Systems Medicine Miller, Michelle; University of Warwick, Warwick Medical School Cappuccio, Francesco; University of Warwick, Warwick Medical School, Division of Health Sciences Banerjee, Prithwish; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiology</td>
</tr>
<tr>
<td>Primary Subject Heading</td>
<td>Cardiovascular medicine</td>
</tr>
<tr>
<td>Secondary Subject Heading</td>
<td>Geriatric medicine</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Heart Failure with Preserved Ejection Fraction, Comorbidities, Pathophysiology, Arterial stiffness</td>
</tr>
</tbody>
</table>
Note from the Editors: Instructions for reviewers of study protocols

Since launching in 2011, BMJ Open has published study protocols for planned or ongoing research studies. If data collection is complete, we will not consider the manuscript.

Publishing study protocols enables researchers and funding bodies to stay up to date in their fields by providing exposure to research activity that may not otherwise be widely publicised. This can help prevent unnecessary duplication of work and will hopefully enable collaboration. Publishing protocols in full also makes available more information than is currently required by trial registries and increases transparency, making it easier for others (editors, reviewers and readers) to see and understand any deviations from the protocol that occur during the conduct of the study.

The scientific integrity and the credibility of the study data depend substantially on the study design and methodology, which is why the study protocol requires a thorough peer-review.

BMJ Open will consider for publication protocols for any study design, including observational studies and systematic reviews.

Some things to keep in mind when reviewing the study protocol:

- Protocol papers should report planned or ongoing studies. The dates of the study should be included in the manuscript.
- Unfortunately we are unable to customize the reviewer report form for study protocols. As such, some of the items (i.e., those pertaining to results) on the form should be scored as Not Applicable (N/A).
- While some baseline data can be presented, there should be no results or conclusions present in the study protocol.
- For studies that are ongoing, it is generally the case that very few changes can be made to the methodology. As such, requests for revisions are generally clarifications for the rationale or details relating to the methods. If there is a major flaw in the study that would prevent a sound interpretation of the data, we would expect the study protocol to be rejected.
The Heart Failure with Preserved Ejection Fraction (HFP EF) Pathophysiology, observational Study (IDENTIFY-HF): does increased arterial stiffness associate with HFP EF, in addition to ageing and vascular effects of co-morbidities? - rationale and design

D. Ali (a,b), N. Callan (a), S. Ennis (c), R. Powell (c), S. McGuire (c,e), G. McGregor (c,e), M.O. Weickert (a,b,d,e), M.A. Miller (b), F.P. Cappuccio (a,b), P. Banerjee (a,b,e)

(a) University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
(b) University of Warwick, Warwick Medical School, Coventry, UK
(c) Department of Cardiac Rehabilitation, Centre for Exercise and Health, University Hospital, Coventry, UK
(d) The ARDEN NET Centre, European Neuroendocrine Tumour Society (ENETS) Centre of Excellence (CoE), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
(e) Health and Life Sciences Faculty Research Centre, Coventry University, Coventry, UK

Keywords: Heart Failure with Preserved Ejection Fraction, Comorbidities, Pathophysiology, Arterial stiffness

ClinicalTrials.gov Identifier: NCT03186833

Corresponding author:
Prof Prithwish Banerjee
Prithwish.banerjee@uhcw.nhs.uk
Abstract

Aims

There has been a paradigm shift proposing that comorbidities are a major contributor towards the heart failure with preserved ejection fraction (HFpEF) syndrome. Furthermore, HFpEF patients have abnormal macro and microvascular function, which may significantly contribute towards altered ventriculo-vascular coupling in these patients. The IDENTIFY-HF study will investigate whether gradually increased arterial stiffness (in addition to ageing) as a result of increasing common comorbidities, such as hypertension and diabetes, is associated with HFpEF.

Methods and analysis:

In our observational study arterial compliance and microvascular function will be assessed in five groups (Groups A to E) of age, sex and BMI matched subjects (age ≥ 70 years in all groups):

Group A; normal healthy volunteers without major comorbidities such as hypertension and diabetes mellitus (control). Group B; patients with hypertension without diabetes mellitus or heart failure (HF). Group C; patients with hypertension and diabetes mellitus without HF. Group D, patients with HFpEF; Group E; patients with heart failure and reduced ejection fraction (HFrEF) (parallel group).

Vascular function and arterial compliance will be assessed using Pulse Wave Velocity, as the primary outcome measure. Further outcome measures include Cutaneous Laser Doppler Flowmetry as a measure of endothelial function, transthoracic echocardiography and exercise tolerance measures. Biomarkers include NT-proBNP, high sensitivity Troponin T, as well as serum galactin-3 as a marker of fibroses.
Ethics and dissemination

The study was approved by the regional research ethics committee (REC), West Midland and Black Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained from the RDI, UHCW NHS Trust. The results will be published in peer-reviewed journals and presented in local, national and international medical society meetings.

Strengths and limitations of this study

- An important observational study aimed towards the understanding of the complex pathophysiology of HFpEF.

- Will provide insight whether the HFpEF syndrome is associated with increased arterial stiffness, as a result of increasing comorbidities.

- Comprehensive study of patients with increasing comorbidities investigating macrovascular/microvascular function, echocardiographic, biochemical and metabolomics to assess endothelial function in age, sex, and BMI-matched groups.

- The limitations of the study is that groups with more comorbidities (e.g. diabetes mellitus, hypertension and chronic kidney disease) should be included to fully investigate the potential effect of increasing comorbidities on arterial stiffness, which in turn, is associated with HFpEF. Further, the cross-sectional design of the study with the related disadvantages
INTRODUCTION

Heart failure (HF) is a major growing public health concern with approximately 20 million patients affected globally, posing a significant health economic burden, with an estimated cost of $108 billion per year worldwide.\(^1\) In the UK alone, approximately 5% of all emergency medical admissions are due to heart failure with an approximate cost to the National Health Service of £1.9 billion per year.\(^2\) Heart failure with preserved ejection fraction (HFpEF) is reported to comprise about 50% of the total heart failure burden and continues to have a high and unchanged mortality over many years, a poor quality of life and similar readmission rates to HFrEF.\(^3\)\(^4\) The prognosis of HFpEF is comparable to systolic heart failure (SHF), now referred to as heart failure with reduced ejection fraction (HFrEF), with an estimated 5-year mortality of around 50%. This is worrying as no treatments that influence outcome in HFpEF have so far been found.\(^5\) Most large-scale pharmacological phase III clinical trials have been unsuccessful.\(^6\)\(^7\) Whilst there is no single reason contributing to the negative result of these trials, the most likely explanation is that our understanding of the pathophysiology of the HFpEF syndrome remains incomplete and we are, therefore, currently unable to produce therapies targeted at the underlying mechanisms causing the syndrome.\(^8\) Therefore, in order to develop evidence-based treatments in patients with HFpEF, the underlying diverse pathophysiology requires further investigation.

Recently, there has been a shift in paradigm whereby comorbidities are thought to contribute significantly to HFpEF syndrome.\(^9\) Furthermore, current evidence strongly suggests that HFpEF patients have abnormal macro-and microvascular function with abnormal ventricular-vascular coupling.\(^10\) However, the effect of comorbidities on arterial stiffness and the HFpEF syndrome remains incompletely understood.

This study aims to investigate the pathophysiological process of HFpEF and this understanding will promote further research, aiding the development of new evidence-based interventions and/or early prevention strategies.
Hypothesis

HFrEF is a complex syndrome which is characterized by signs and symptoms of heart failure and a normal or a close to normal ejection fraction, evidence of left ventricular diastolic dysfunction, structural heart disease, altered left ventricular filling (LV) and raised brain natriuretic peptide (BNP). The complete pathophysiology is not known, however it is widely accepted that it is associated with cardiac and non-cardiac comorbidities. Cardiac abnormalities include altered atrial function, subtle alterations in LV systolic function and/or chronotropic incompetence. Non-cardiac comorbidities, for example hypertension, diabetes mellitus, anaemia, pulmonary or renal diseases and obesity may contribute to the HFrEF syndrome. In terms of pathophysiology, diastolic dysfunction is a prominent feature of HFrEF patients to which many factors contribute including both myocardial and vascular stiffening.

HFrEF patients are known to have altered vascular function. Balmain et al. investigated the comparison in arterial compliance, venous capacitance and microvascular vasodilator function in 3 patients’ groups with HFrEF, HFrEF and normal volunteers (non-HF). All the groups had coronary artery disease (CAD). They found that there was reduced vascular compliance (increased arterial stiffness, decreased venous capacitance) in the HFrEF group compared to the HFrEF and non-HF groups. More recently, macro-and microvascular function was compared between HFrEF and hypertensive patients. This study found that there was decreased microvascular function with increase in arterial stiffness and depressed endothelial function in the forearm vasculature in the HFrEF group compared to the hypertensive group. These studies highlight the fact that abnormal vasculature is present and may be an important contributor to the HFrEF syndrome. Although the
groups in the above-mentioned studies were matched for age and sex, what remains unclear is why
certain patients of the same age and sex suffer from HFpEF whilst others do not. There is good
evidence that hypertension\textsuperscript{17}, diabetes mellitus\textsuperscript{18}, and chronic kidney disease\textsuperscript{19} all increase vascular
resistance on their own. Aging itself is known to be an independent risk factor for arterial stiffness
and increase in pulse wave velocity.\textsuperscript{20, 21} It is therefore reasonable to consider that HFpEF may not be
due to a primary cardiac pathology but rather an end-result of non-cardiac comorbidities affecting
vascular function and resistance with perhaps some secondary cardiac involvement. We
hypothesized therefore, that arterial stiffness increases with comorbidities, on top of effects of
normal ageing (as illustrated in Figure 1), contributing towards the HFpEF syndrome. It is possible
that a gradual increase in arterial stiffness may be causing early fatigue of the cardiac muscles (as it
struggles to pump into an ever-increasing high-pressure vascular circuit) resulting in elevation of left
ventricular end diastolic pressure and subsequently HFpEF\textsuperscript{22}.

METHODS

Study Design

Single-centre, observational study in 5 age, sex and BMI matched groups varying for the presence or
absence of diabetes, hypertension or heart failure.

Definitions

Heart failure in our study is defined as: a) relevant symptoms/signs/radiographic findings as
indicated by Boston criteria \textsuperscript{23} and b) need for diuretic therapy. Preserved LV systolic function is
defined as a LV ejection fraction (LVEF) of $\geq$50%, measured by echocardiography. Impaired LV systolic function will be defined as a LVEF of $<40\%$ in accordance with the European Society of Cardiology guidelines on heart failure. LVEF will be calculated using semi-quantitative assessment with 16 segment wall motion scoring$^{24}$. HFpEF, is defined as signs and symptoms of HF with LVEF$\geq$50% and raised natriuretic peptides (BNP$>$35pg/ml or NT-proBNP$>$125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.

Hypertension is defined in this study as a documented resting clinic systolic blood pressure (SBP) $\geq$140 mmHg or Diastolic Blood Pressure (DBP) $\geq$90mmHg. Diabetes mellitus will be defined according to the World Health Organization (WHO) criteria.$^{25}$

Study Setting

The study will be conducted at two sites: the cardiology research department at University Hospitals Coventry & Warwickshire (UHCW) NHS Trust and at the cardiac rehabilitation facility of the hospital. The study assessments are expected to be undertaken during a single visit, however a second visit will be arranged if all the assessments are not completed.

Study Population

Patients will be matched according to age, gender, Body Mass Index (BMI) and allocated to 5 different groups. All patients will be aged 70 years or above.

The first four groups will constitute: group A) normal healthy volunteers without major comorbidities including hypertension and diabetes, group B) patients with hypertension without diabetes mellitus, group C) patients with hypertension AND diabetes mellitus, and group D) patients
with HFrEF. The fifth, parallel group E will comprise the HFrEF group. In order to make meaningful comparison between the groups 21 patients each are planned to be recruited in groups A to D and 11 in group E determined by sample size calculation.

**Aims**

We plan to assess vascular function, and cardiovascular performance in different cohorts (figure 2). Arterial resistance measured by pulse wave velocity (PWV) will be the primary outcome measure and will be compared between groups A to D. A separate comparison will be made between groups D and E. We intend to investigate if there is increased arterial resistance from group “A” to group “D” and if there is a significant difference in arterial resistance between groups “D” and “E. The secondary measures will focus on endothelial function (Laser Doppler measurements) and other cardiovascular performance measures; peak VO2 by Cardio-Pulmonary Exercise Test (CPEX), and 6-minute walk distance. Blood samples will be taken for NT-proBNP, high sensitivity Troponin T and serum will be stored for testing later for vascular biomarkers and galectin-3.

**Inclusion Criteria**

- **Group A:** healthy males or females aged ≥ 70 years without major systemic illnesses including hypertension and diabetes mellitus.
- **Group B:** males or females aged ≥ 70 years with hypertension only.
- **Group C:** males or females aged ≥70 years with hypertension and diabetes mellitus but without HF.
- **Group D:** males or females aged ≥70 years with HFrEF.
- **Group E:** males or females aged ≥ 70 years with HFrEF.
Exclusion criteria

- Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months, or urgent percutaneous coronary intervention (PCI) within 30 days of entry.
- Patients who have had an MI, coronary artery bypass graft (CABG) or other event within the 6 months prior to entry unless an echo measurement performed after the event confirms a LVEF ≥50%.
- Current acute decompensated HF requiring intravenous therapy
- Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, haemoglobin (Hb) <10 g/dl, or body mass index (BMI) > 40 kg/m2.
- Severe left-sided valvular heart disease
- Hypotension (systolic BP <100 mm Hg).
- Severe Liver failure
- Primary pulmonary hypertension
- Bedbound/immobile patients
- Chronic renal failure with creatinine of >250 μmol/l
- Significant Peripheral Vascular Disease (PVD), defined as having signs of absent peripheral pulses or reported claudication pain or documented history of PVD
Sample size calculation and statistical analysis

The sample size calculation is based on estimates obtained in studies reported by Balmain et al.\textsuperscript{26} and Marechaux et al.\textsuperscript{27} The aim is to detect a difference in the primary outcome; Pulse Wave Velocity (PWV), between the five groups of patients recruited to the study with the significance level being set at 5\% if the \( p \) value is less than 0.05. The estimates range from a mean PWV of 8.6 m/s for the control group to 11.3 m/s for the HFpEF group and the within group standard deviation is assumed to be SD=1.7 m/s and equal for each group. No estimate of the mean PWV was available in the literature for the hypertension and Diabetes Mellitus group, so this value was assumed to be in exactly in the middle of the hypertension and HFpEF mean. A sample size of \( n=11 \) for HFrEF patients and \( n=21 \) for all other groups will allow to detect a difference in PWV between the five groups for the aforementioned configuration of means and SD with 80\% power using the overall F-test in a one-way ANOVA. The study would additionally be sufficiently powered for the pair-wise comparison of the control group with the hypertension group and the control group with the HFpEF group. Statistical analysis will be performed with IBM SPSS Statistics for Windows, version 22.0. Descriptive statistics will be given as number (percentage), as average (±SD) or median (interquartile range).
Study Procedures

Participants will attend our Research Unit in the morning. To avoid confounding factors for vascular measurements, participants and will be asked to abstain from caffeine and tobacco for 12 hours, and to omit their morning blood pressure medication. Vascular function studies will be carried out in a quiet, temperature-controlled (21–23 °C) room with subjects in the supine position, following at least 10 min of rest. Arterial compliance will be assessed using applanation tonometry to measure aortic PWV. Cutaneous microvascular function will be assessed by Laser Doppler Flowmetry, after which the blood test and TTE measurements will be performed. Subsequently, patients will be asked to undertake the 6-MWT and CPEX test (figure 2).

Screening and Recruitment

Group A: Participants will be recruited via the UHCW Hospital Radio, senior citizen’s group in the community, and via friends and relatives of colleagues. These patients will receive an invitation letter and participant information sheet to read, they will then be contacted by the study
coordinator at least 24 hours after receiving the invitation letter to answer any questions. If the participant is interested in taking part in the study, they will be invited for a screening visit at UHCW to confirm their eligibility. This will involve a full medical history, physical examination, blood pressure measurement and blood tests (FBC, Glucose, HbA1c, and renal function). If the eligibility criteria are met, the study appointment will be organised.

**Group B and C:** Patients will be approached and screened for eligibility at the hypertension and diabetes outpatient clinics at UHCW. Eligible participants will receive an invitation letter and participant information sheet. They will then be contacted by the study coordinator at least 24 hours later to answer any questions, and to organise a study appointment.

**Group D and E:** Patients will be approached and screened for the eligibility criteria at the HF community clinic. Eligible participants will receive an invitation letter and participant information sheet. They will then be contacted by the study coordinator after at least 24 hours to answer any questions, and to organise a study appointment.

**Study Assessments**

Participants in all groups will have the same assessments as follows (table 1):

**Blood pressure and heart rate measurement**

Heart rate and one brachial blood pressure measurement will be recorded over a 30s time period. These measurements will be performed 3 times for each subject and averaged.

**Blood tests** will include full blood count, renal function and electrolytes, liver function tests, NT-proBNP, and high-sensitive cardiac Troponin T (hs-cTnT). Blood samples will be frozen in the Tissue
bank at UHCW for further tests such as vascular and other biomarkers e.g. galectin-3 to be performed at a later date.

Urinalysis will be performed from a mid-stream urine sample obtained for albumin and creatinine levels. This will further be stored at the Tissue Bank UHCW to be analysed at a later date for metabolite profiles (“metabolomics”), related to cardiovascular risk and insulin resistance.

Transthoracic echocardiography (TTE) will include measurements of cardiac chamber sizes, ventricular function including LVEF, indices of LV diastolic function, assessment of valvular heart disease, tissue Doppler imaging and strain rate imaging. Furthermore, right ventricular structure and function and pulmonary artery pressures will be assessed.

Exercise tolerance will be assessed by a 6-minute walk test and a CPEX in each patient. The CPEX test will involve measurement of the oxygen consumption and carbon dioxide production and heart rate and blood pressure monitoring whilst exercising on an exercise bike.

Pulse wave velocity protocol

Arterial resistance will be assessed using pulse wave velocity. Aortic PWV will be evaluated using a high fidelity micromanometer (SPC-301; Millar Instruments, Texas, USA) coupled with the SphygmoCorTM system (SphygmoCor BPAS; PWV Medical, Sydney, Australia). A hand-held micromanometer-tipped probe will be applied to the skin overlying the radial, femoral and carotid arteries at the point of maximal arterial pulsation. Gated to a simultaneous electrocardiogram, the pulse wave will be recorded at each point. This data, in combination with the measured body surface distance between the two points, will be incorporated by the software program to calculate
PWV in meters per second (m/s). The measurements will be repeated 3 times and the average PWV will be used for analysis.

**Laser Doppler Flowmetry (LDF) Protocol**

The forearm cutaneous blood flow will be measured at rest and during reactive hyperaemia by using Laser Doppler Flowmetry (LDF), in accordance to the Fizeau-Doppler principle. Measurements of cutaneous blood flow will be expressed in perfusion units (PU) and the Laser Doppler signal will be continuously monitored on a computer (Moor instruments, VMS software V4.06) coupled with Moor instruments system (moorVMS-VASC). The thenar eminence will be used for the placement of the LDF probe (VP1T/7), consistently at the same place, before and post the occlusive reactive hyperaemia manoeuvre. The room temperature will be maintained at 22 degrees Celsius during forearm cutaneous blood flow measurements. The reactive hyperaemia will be produced by occluding the forearm blood flow with a pneumatic cuff inflated to a pressure of 50 mm Hg above the Systolic Blood Pressure for 3 minutes. The signal obtained during complete arterial occlusion will be taken as the biologic zero for cutaneous blood flow measurements before and during reactive hyperaemia. Resting flow will be taken as the average of a 6-minute stable LDF recording. The definition of the measurements taken are shown in figure 3 and the power spectral density (PSD) will be measured using the basic fast Fourier transform algorithm.

**Cardio-Pulmonary Exercise Test (CPEX)**

Exercise tolerance will be assessed by 6-minute walk test and CPEX, conducted in accordance with existing guidelines. For the walk test, participants will walk as far as possible in six minutes along a flat, obstacle free corridor, turning 180 degrees every 30m. For CPEX, participants will pedal a cycle ergometer at 70 rpm until volitional fatigue, using a ramp protocol. Breath-by-breath measurement of O\textsuperscript{2} consumption, CO\textsuperscript{2} production and ventilation will be used to determine key cardiorespiratory
parameters including peak O$_2$ uptake (VO$_2$ peak), VO$_2$ at the anaerobic threshold (VO$_2$ AT) and ventilatory efficiency (VE/VCO$_2$). Blood pressure, ECG and O$_2$ saturation will be continuously monitored. Criteria for a peak test will include respiratory exchange ratio (RER) >1.10$^{32}$.

**Blinding**

In order to reduce observer-bias the operator involved in the assessments of the primary outcome (pulse wave velocity) will be blinded to the comorbidities of the group of patients (A to E).

**Primary Outcome**

Our primary outcome will be a difference in arterial resistance between each of the five groups, as measured by aortic PWV. In addition, specific comparisons will be made between the control and hypertension groups as well as the control and HFpEF groups.

**Secondary Outcomes**

The secondary outcomes are to assess and compare endothelial function and cardiovascular performance in all groups as measured by the following:

- **Blood tests**: NTproBNP, high sensitivity Troponin T, Galectin-3
- **Urinalysis**: Albumin, Creatinine and Metabolite profiles (“metabolomics”), related to cardiovascular risk and insulin resistance
- **Transthoracic echocardiography (TTE)** indices of LV diastolic function, tissue Doppler imaging, strain rate imaging and measuring flow with pulsed-wave Doppler echocardiography interrogating the LV outflow tract.
- **Exercise tolerance**: 6-minute walk test and a Cardiopulmonary Exercise Test (CPEX)

End of study definition

The study will be closed at the last patient’s study visit.

Study funding and sponsor

The study has been funded by a research grant from the West Midlands Clinical Research Network, National Institute of Health Research, UK. The study is sponsored by the Research, Development & Innovation department of the University Hospitals Coventry & Warwickshire NHS Trust (RDI, UHCW), UK.

Study oversight

The Study will be monitored and overseen by the Study Management Group and the Research, Development and Innovation Department at UHCW.

Ethical approval and research governance

The study was approved by the regional research ethics committee (REC), West Midland and Black Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained from the RDI, UHCW NHS Trust. The study will be conducted in compliance with the principles of the GCP guidelines and in accordance with all applicable regulatory guidance, including, but not limited to, the Research Governance Framework and the Health Research Authority, UK. Progress reports
and a final report at the conclusion of the study will be submitted to the approving REC within the timelines defined by the committee.

**Patient and public involvement**

Patient involvement has been essential to the design of and protocol of the study. Consultation has been obtained from patient and public involvement (PPI) representatives, which led to the tests being allowed to be done over two visits after screening. The non-invasive nature of the investigations has been particularly likened by the PPI representative. Furthermore, optional transport was provided to participants after their recommendation. Patients seen in the relevant outpatient department will be invited to participate in the study. On-going PPI input will occur during study steering committee. The results of the study will be disseminated to all the participants via post.

**Dissemination and impact**

The hypothesis on which this study is based has been published. Error! Bookmark not defined. The results of the study will be presented at national and international conferences and released in appropriate media outlets, including social media. The results are expected to be published in peer-reviewed journals and presented in local, national and international medical scientific congresses and meetings. The study is anticipated to shed light on whether vascular stiffness is an important determinant of HFpEF which in turn could potentially encourage research for new therapeutic targets.

**Competing interest**

None declared
Contributors

Contributor PB is the chief investigator for the study and DA leading on writing the protocol, ethics application and preparation of this manuscript. FC, MW, MM all contributed fully to study design. GM, NC, SM, SE and RP contributed from their respective discipline and authored the relevant section of the protocol and manuscript. All authors read and approved the final version of the manuscript.

Table 1: Schedule of measures for every participant within the study.

GROUP A ONLY: SEPARATE SCREENING VISIT PRIOR TO THE STUDY VISIT TO CHECK THAT THE PARTICIPANTS MEET THE ELIGIBILITY CRITERIA. FULL MEDICAL HISTORY, PHYSICAL EXAMINATION,
BLOOD PRESSURE AND BLOOD TESTS (FBC, GLUCOSE, HBA1C, AND RENAL FUNCTION).

<table>
<thead>
<tr>
<th>TIME OF DAY</th>
<th>Procedures/Assessments*</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORNING</td>
<td>Eligibility check</td>
</tr>
<tr>
<td></td>
<td>Informed consent</td>
</tr>
<tr>
<td></td>
<td>Demographic data (DOB, sex, ethnicity, height and weight)</td>
</tr>
<tr>
<td></td>
<td>Relevant clinical history</td>
</tr>
<tr>
<td></td>
<td>Current medications</td>
</tr>
<tr>
<td></td>
<td>Blood pressure and Heart rate</td>
</tr>
<tr>
<td></td>
<td>Pulse Wave velocity (PWV) to measure arterial resistance</td>
</tr>
<tr>
<td></td>
<td>Laser Doppler to measure microvascular function</td>
</tr>
<tr>
<td></td>
<td>Blood tests: Full blood count, renal function and electrolytes, liver function tests, NT-proBNP, high-sensitive cardiac Troponin T (hs-cTnT). Samples will be frozen and stored for future analysis of vascular and other biomarkers e.g. Galectin-3</td>
</tr>
<tr>
<td></td>
<td>Urine test: Albumin and Creatinine. Samples will be frozen and stored for future analysis of metabolite profiles</td>
</tr>
<tr>
<td>LUNCH</td>
<td>Transthoracic echocardiography (TTE): tissue Doppler imaging and strain rate imaging</td>
</tr>
<tr>
<td></td>
<td>6-minute walk test</td>
</tr>
<tr>
<td></td>
<td>Cardiopulmonary Exercise Test (CPEX)</td>
</tr>
</tbody>
</table>

All assessments will be aimed to be completed in a single visit. However, a possible second visit can be arranged either at Atrium Health or University Hospitals Coventry and Warwickshire NHS Trust for completion of all assessments, if require.
13. References


7 Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions Heart Published Online First: 05 January 2018. doi: 10.1136/heartjnl-2016-310790.


10 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016

11 McMurray JJ, Adamopoulos S, Anker SD, et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847.


15 Balmain S, Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function, European Journal of Heart Failure 9 (2007) 865–871

16 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


www.diabetes.org.uk

Balmain S, Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function, European Journal of Heart Failure 9 (2007) 865–871

Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on

25 www.diabetes.org.uk

26 Balmain S, Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function, European Journal of Heart Failure 9 (2007) 865–871

27 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


29 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


Figure 1: Overview of the hypothesis behind the IDENTIFY-HF study

Arterial stiffness
Normal part of ageing (elderly >70yrs) even without common comorbidities (Group 1)

Further increase in arterial stiffness
Elderly patients with hypertension (Group 2)

Even greater arterial stiffness
Elderly patients with diabetes and hypertension (Group 3)
**Figure 2: Study Flow Chart**

- **Screening (Group A-E)**
  - Consent
  - Baseline demographics/history and physical examination
  - **Testing**
    - 1) Bloods (FBC, U&E, LFT, Glucose, Hba1c, hs-cTnT, NTproBNP, serum galectin-3)
    - 2) Laser Doppler Flowmetry
    - 3) PWV
    - 4) TTE
    - 5) CPFEx and/or 6-MWT

All assessments aimed to be completed in a single visit. A possible second visit can be arranged either for completion of all assessments, if required.
Figure 3: Laser Doppler Flowmetry for assessment of endothelial function. Schematic representation of flow (perfusion units) as a function of time in rest, after arterial occlusion and after cuff release. (adapted with permission of Moor Diagnostics)

**Terminology**

- Average1: averaging of raw 0.1s-smoothed data for calculating fast responses (all except TM, TH);
- Average2: averaging of raw 0.1s-smoothed data for calculating slow responses (ie TM and TH);
- RL (Resting Level): the average value before inflation;
- BZ (Biological Zero): the average value during second half of pressure-holding period;
- ML (Maximum Level): maximum value after release of cuff pressure;
- AO (Area of Occlusion): area between resting level and trace during pressure-holding period;
- AH (Area of Hyperaemia): area between resting level and trace from TR to post-maximum RL;
- T0 (Time of Zero Increase): interval after release before trace increases;
- TR (Time to Recovery): interval between release and trace restoring to RL;
- TM (Time to Maximum Level): interval between release and Maximum Value;
- TH (Time to Half Decay): interval from release to mid-decay value after maximum, ie value = (ML+RL)/2;
- Slope (MF - BZ)/TM: the slope of trace increase from release to Maximum Value;
- Index (PORH Index): area 1min after release / area 1min before inflation;
- Peak (Transient Peak): raw 0.1s-smoothed peak within first 2s after release with peak duration less than 4s.

Figure 3

90x90mm (300 x 300 DPI)
The Heart Failure with Preserved Ejection Fraction (HFpEF) Pathophysiology, observational Study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of co-morbidities? - rationale and design

D. Ali (a,b), N. Callan (a), S. Ennis (c), R. Powell (c), S. McGuire (c,e), G. McGregor (c,e), M.O. Weickert (a,b,d,e), M.A. Miller (b), F.P. Cappuccio (a,b), P. Banerjee (a,b,e)

(a) University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
(b) University of Warwick, Warwick Medical School, Coventry, UK
(c) Department of Cardiac Rehabilitation, Centre for Exercise and Health, University Hospital, Coventry, UK
(d) The ARDEN NET Centre, European Neuroendocrine Tumour Society (ENETS) Centre of Excellence (CoE), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
(e) Health and Life Sciences Faculty Research Centre, Coventry University, Coventry, UK

Keywords: Heart Failure with Preserved Ejection Fraction, Comorbidities, Pathophysiology, Arterial stiffness

ClinicalTrials.gov Identifier: NCT03186833

Corresponding author:
Prof Prithwish Banerjee
Prithwish.banerjee@uhcw.nhs.uk
Abstract

Aims

There has been a paradigm shift proposing that comorbidities are a major contributor towards the heart failure with preserved ejection fraction (HFpEF) syndrome. Furthermore, HFpEF patients have abnormal macro and microvascular function, which may significantly contribute towards altered ventrículo-vascular coupling in these patients. The IDENTIFY-HF study will investigate whether gradually increased arterial stiffness (in addition to ageing) as a result of increasing common comorbidities, such as hypertension and diabetes, is associated with HFpEF.

Methods and analysis:

In our observational study, arterial compliance and microvascular function will be assessed in five groups (Groups A to E) of age, sex and BMI matched subjects (age ≥ 70 years in all groups):

Group A; normal healthy volunteers without major comorbidities such as hypertension and diabetes mellitus (control). Group B; patients with hypertension without diabetes mellitus or heart failure (HF). Group C; patients with hypertension and diabetes mellitus without HF. Group D, patients with HFpEF; Group E; patients with heart failure and reduced ejection fraction (HFrEF) (parallel group).

Vascular function and arterial compliance will be assessed using Pulse Wave Velocity, as the primary outcome measure. Further outcome measures include Cutaneous Laser Doppler Flowmetry as a measure of endothelial function, transthoracic echocardiography and exercise tolerance measures. Biomarkers include NT-proBNP, high sensitivity Troponin T, as well as serum galactin-3 as a marker of fibroses.
Ethics and dissemination

The study was approved by the regional research ethics committee (REC), West Midland and Black Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained from the RDI, UHCW NHS Trust. The results will be published in peer-reviewed journals and presented in local, national and international medical society meetings.

Strengths and limitations of this study

- An important observational study aimed towards the understanding of the complex pathophysiology of HfPEF.

- Will provide insight whether the HfPEF syndrome is associated with increased arterial stiffness, as a result of increasing comorbidities.

- Comprehensive study of patients with increasing comorbidities investigating macrovascular/microvascular function, echocardiographic, biochemical and metabolomics to assess endothelial function in age, sex, and BMI-matched groups.

- The limitations of the study is that groups with more comorbidities (e.g. diabetes mellitus, hypertension and chronic kidney disease) should be included to fully investigate the potential effect of increasing comorbidities on arterial stiffness, which in turn, is associated with HfPEF. Further, the cross-sectional design of the study with the related disadvantages

INTRODUCTION

Heart failure (HF) is a major growing public health concern with approximately 20 million patients affected globally, posing a significant health economic burden, with an estimated cost of $108 billion
per year worldwide.\textsuperscript{1} In the UK alone, approximately 5\% of all emergency medical admissions are due to heart failure with an approximate cost to the National Health Service of £1.9 billion per year.\textsuperscript{2} Heart failure with preserved ejection fraction (HFpEF) is reported to comprise about 50\% of the total heart failure burden and continues to have a high and unchanged mortality over many years, a poor quality of life and similar readmission rates to HFrEF.\textsuperscript{3,4} The prognosis of HFpEF is comparable to systolic heart failure (SHF), now referred to as heart failure with reduced ejection fraction (HFrEF), with an estimated 5-year mortality of around 50\%. This is worrying as no treatments that influence outcome in HFpEF have so far been found.\textsuperscript{5} Most large-scale pharmacological phase III clinical trials have been unsuccessful.\textsuperscript{6,7} Whilst there is no single reason contributing to the negative result of these trials, the most likely explanation is that our understanding of the pathophysiology of the HFpEF syndrome remains incomplete and we are, therefore, currently unable to produce therapies targeted at the underlying mechanisms causing the syndrome.\textsuperscript{8} Therefore, in order to develop evidence-based treatments in patients with HFpEF, the underlying diverse pathophysiology requires further investigation.

Recently, there has been a shift in paradigm whereby comorbidities are thought to contribute significantly to HFpEF syndrome.\textsuperscript{9} Furthermore, current evidence strongly suggests that HFpEF patients have abnormal macro- and microvascular function with abnormal ventricular-vascular coupling.\textsuperscript{10} However, the effect of comorbidities on arterial stiffness and the HFpEF syndrome remains incompletely understood.

This study aims to investigate the pathophysiological process of HFpEF and this understanding will promote further research, aiding the development of new evidence-based interventions and/or early prevention strategies.
Hypothesis

HFrEF is a complex syndrome which is characterized by signs and symptoms of heart failure and a normal or a close to normal ejection fraction, evidence of left ventricular diastolic dysfunction, structural heart disease, altered left ventricular filling (LV) and raised brain natriuretic peptide (BNP). The complete pathophysiology is not known, however it is widely accepted that it is associated with cardiac and non-cardiac comorbidities. Cardiac abnormalities include altered atrial function, subtle alterations in LV systolic function and/or chronotropic incompetence. Non-cardiac comorbidities, for example hypertension, diabetes mellitus, anaemia, pulmonary or renal diseases and obesity may contribute to the HFrEF syndrome. In terms of pathophysiology, diastolic dysfunction is a prominent feature of HFrEF patients to which many factors contribute including both myocardial and vascular stiffening.

HFrEF patients are known to have altered vascular function. Balmain et al. investigated the comparison in arterial compliance, venous capacitance and microvascular vasodilator function in 3 patients’ groups with HFrEF, HFrEF and normal volunteers (non-HF). All the groups had coronary artery disease (CAD). They found that there was reduced vascular compliance (increased arterial stiffness, decreased venous capacitance) in the HFrEF group compared to the HFrEF and non-HF groups. More recently, macro-and microvascular function was compared between HFrEF and hypertensive patients. This study found that there was decreased microvascular function with increase in arterial stiffness and depressed endothelial function in the forearm vasculature in the HFrEF group compared the hypertensive group. These studies highlight the fact that abnormal vasculature is present and may be an important contributor to the HFrEF syndrome. Although the groups in the above-mentioned studies were matched for age and sex, what remains unclear is why certain patients of the same age and sex suffer from HFrEF whilst others do not. There is good evidence that hypertension, diabetes mellitus, and chronic kidney disease all increase vascular
resistance on their own. Aging itself is known to be an independent risk factor for arterial stiffness and increase in pulse wave velocity. \textsuperscript{20, 21} It is therefore reasonable to consider that HFpEF may not be due to a primary cardiac pathology but rather an end-result of non-cardiac comorbidities affecting vascular function and resistance with perhaps some secondary cardiac involvement. We hypothesized therefore, that arterial stiffness increases with comorbidities, on top of effects of normal ageing (as illustrated in Figure 1), contributing towards the HFpEF syndrome. It is possible that a gradual increase in arterial stiffness may be causing early fatigue of the cardiac muscles (as it struggles to pump into an ever-increasing high-pressure vascular circuit) resulting in elevation of left ventricular end diastolic pressure and subsequently HFpEF.\textsuperscript{22}

\section*{METHODS}

\textbf{Study Design}

Single-centre, observational study in 5 age, sex and BMI matched groups varying for the presence or absence of diabetes, hypertension or heart failure.

\textbf{Definitions}

Heart failure in our study is defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria \textsuperscript{23} and b) need for diuretic therapy. Preserved LV systolic function is defined as a LV ejection fraction (LVEF) of $ \geq 50\% $, measured by echocardiography. Impaired LV systolic function will be defined as a LVEF of $ < 40\% $ in accordance with the European Society of Cardiology guidelines on heart failure. LVEF will be calculated using semi-quantitative assessment
with 16 segment wall motion scoring\textsuperscript{24}. HFpEF, is defined as signs and symptoms of HF with
LVEF \geq 50\% and raised natriuretic peptides (BNP > 35pg/ml or NT-proBNP > 125pg/ml) along with one
other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on
TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with
heart failure within 12 months prior to study entry.

Hypertension is defined in this study as a documented resting clinic systolic blood pressure (SBP)
\geq 140 \text{ mmHg} or Diastolic Blood Pressure (DBP) \geq 90\text{mmHg}. Diabetes mellitus will be defined according
to the World Health Organization (WHO) criteria.\textsuperscript{25}

Study Setting

The study will be conducted at two sites: the cardiology research department at University Hospitals
Coventry & Warwickshire (UHCW) NHS Trust and at the cardiac rehabilitation facility of the hospital.
The study assessments are expected to be undertaken during a single visit, however a second visit
will be arranged if all the assessments are not completed.

Study Population

Patients will be matched according to age, gender, Body Mass Index (BMI) and allocated to 5
different groups. All patients will be aged 70 years or above.

The first four groups will constitute: group A) normal healthy volunteers without major
comorbidities including hypertension and diabetes, group B) patients with hypertension without
diabetes mellitus, group C) patients with hypertension AND diabetes mellitus, and group D) patients
with HFpEF. The fifth, parallel group E will comprise the HFrEF group. In order to make meaningful
comparison between the groups 21 patients each are planned to be recruited in groups A to D and
11 in group E determined by sample size calculation.
Aims

We plan to assess vascular function, and cardiovascular performance in different cohorts (figure 2). Arterial resistance measured by pulse wave velocity (PWV) will be the primary outcome measure and will be compared between groups A to D. A separate comparison will be made between groups D and E. We intend to investigate if there is increased arterial resistance from group “A” to group “D” and if there is a significant difference in arterial resistance between groups “D” and “E. The secondary measures will focus on endothelial function (Laser Doppler measurements) and other cardiovascular performance measures; peak VO2 by Cardio-Pulmonary Exercise Test (CPEX), and 6-minute walk distance. Blood samples will be taken for NT-proBNP, high sensitivity Troponin T and serum will be stored for testing later for vascular biomarkers and galectin-3.

Inclusion Criteria

- Group A: healthy males or females aged ≥ 70 years without major systemic illnesses including hypertension and diabetes mellitus.
- Group B: males or females aged ≥ 70 years with hypertension only.
- Group C: males or females aged ≥70 years with hypertension and diabetes mellitus but without HF.
- Group D: males or females aged ≥70 years with HFP EF.
- Group E: males or females aged ≥ 70 years with HFrEF.
Exclusion criteria

- Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months, or urgent percutaneous coronary intervention (PCI) within 30 days of entry.
- Patients who have had an MI, coronary artery bypass graft (CABG) or other event within the 6 months prior to entry unless an echo measurement performed after the event confirms a LVEF ≥50%.
- Current acute decompensated HF requiring intravenous therapy
- Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, haemoglobin (Hb) <10 g/dl, or body mass index (BMI) > 40 kg/m2.
- Severe left-sided valvular heart disease
- Hypotension (systolic BP <100 mm Hg).
- Severe Liver failure
- Primary pulmonary hypertension
- Bedbound/immobile patients
- Chronic renal failure with creatinine of >250 μmol/l
- Significant Peripheral Vascular Disease (PVD), defined as having signs of absent peripheral pulses or reported claudication pain or documented history of PVD
Sample size calculation and statistical analysis

The sample size calculation is based on estimates obtained in studies reported by Balmain et al.\textsuperscript{26} and Marechaux et al.\textsuperscript{27} The aim is to detect a difference in the primary outcome; Pulse Wave Velocity (PWV), between the five groups of patients recruited to the study with the significance level being set at 5% if the \( p \) value is less than 0.05. The estimates range from a mean PWV of 8.6 m/s for the control group to 11.3 m/s for the HFrEF group and the within group standard deviation is assumed to be SD=1.7 m/s and equal for each group. No estimate of the mean PWV was available in the literature for the hypertension and Diabetes Mellitus group, so this value was assumed to be in exactly in the middle of the hypertension and HFrEF mean. A sample size of \( n=11 \) for HFrEF patients and \( n=21 \) for all other groups will allow to detect a difference in PWV between the five groups for the aforementioned configuration of means and SD with 80\% power using the overall F-test in a one-way ANOVA. The study would additionally be sufficiently powered for the pair-wise comparison of the control group with the hypertension group and the control group with the HFrEF group.

Statistical analysis will be performed with IBM SPSS Statistics for Windows, version 22.0. Descriptive statistics will be given as number (percentage), as average (±SD) or median (interquartile range).
Study Procedures

Participants will attend our Research Unit in the morning. To avoid confounding factors for vascular measurements, participants will be asked to abstain from caffeine and tobacco for 12 hours, and to omit their morning blood pressure medication. Vascular function studies will be carried out in a quiet, temperature-controlled (21–23 °C) room with subjects in the supine position, following at least 10 min of rest. Arterial compliance will be assessed using applanation tonometry to measure aortic PWV. Cutaneous microvascular function will be assessed by Laser Doppler Flowmetry, after which the blood test and TTE measurements will be performed. Subsequently, patients will be asked to undertake the 6-MWT and CPEX test (figure 2).

Screening and Recruitment

Group A: Participants will be recruited via the UHCW Hospital Radio, senior citizen’s group in the community, and via friends and relatives of colleagues. These patients will receive an invitation letter and participant information sheet to read, they will then be contacted by the study coordinator at least 24 hours after receiving the invitation letter to answer any questions. If the participant is interested in taking part in the study, they will be invited for a screening visit at UHCW to confirm their eligibility. This will involve a full medical history, physical examination, blood
pressure measurement and blood tests (FBC, Glucose, HbA1c, and renal function). If the eligibility
criteria are met, the study appointment will be organised.

**Group B and C:** Patients will be approached and screened for eligibility at the hypertension and
diabetes outpatient clinics at UHCW. Eligible participants will receive an invitation letter and
participant information sheet. They will then be contacted by the study coordinator at least 24 hours
later to answer any questions, and to organise a study appointment.

**Group D and E:** Patients will be approached and screened for the eligibility criteria at the HF
community clinic. Eligible participants will receive an invitation letter and participant information
sheet. They will then be contacted by the study coordinator after at least 24 hours to answer any
questions, and to organise a study appointment.

**Study Assessments**

Participants in all groups will have the same assessments as follows (table 1):

**Blood pressure and heart rate measurement**

Heart rate and one brachial blood pressure measurement will be recorded over a 30s time period.

These measurements will be performed 3 times for each subject and averaged.

**Blood tests** will include full blood count, renal function and electrolytes, liver function tests, NT-
proBNP, and high-sensitive cardiac Troponin T (hs-cTnT). Blood samples will be frozen in the Tissue
bank at UHCW for further tests such as vascular and other biomarkers e.g. galectin-3 to be
performed at a later date.
Urinalysis will be performed from a mid-stream urine sample obtained for albumin and creatinine levels. This will further be stored at the Tissue Bank UHCW to be analysed at a later date for metabolite profiles (“metabolomics”), related to cardiovascular risk and insulin resistance.

Transthoracic echocardiography (TTE) will include measurements of cardiac chamber sizes, ventricular function including LVEF, indices of LV diastolic function, assessment of valvular heart disease, tissue Doppler imaging and strain rate imaging. Furthermore, right ventricular structure and function and pulmonary artery pressures will be assessed.

Exercise tolerance will be assessed by a 6-minute walk test and a CPEX in each patient. The CPEX test will involve measurement of the oxygen consumption and carbon dioxide production and heart rate and blood pressure monitoring whilst exercising on an exercise bike.

Pulse wave velocity protocol

Arterial resistance will be assessed using pulse wave velocity. Aortic PWV will be evaluated using a high fidelity micromanometer (SPC-301; Millar Instruments, Texas, USA) coupled with the SphygmoCorTM system (SphygmoCor BPAS; PWV Medical, Sydney, Australia). A hand-held micromanometer-tipped probe will be applied to the skin overlying the radial, femoral and carotid arteries at the point of maximal arterial pulsation. Gated to a simultaneous electrocardiogram, the pulse wave will be recorded at each point. This data, in combination with the measured body surface distance between the two points, will be incorporated by the software program to calculate PWV in meters per second (m/s). The measurements will be repeated 3 times and the average PWV will be used for analysis.
Laser Doppler Flowmetry (LDF) Protocol

The forearm cutaneous blood flow will be measured at rest and during reactive hyperaemia by using Laser Doppler Flowmetry (LDF), in accordance to the Fizeau-Doppler principle. Measurements of cutaneous blood flow will be expressed in perfusion units (PU) and the Laser Doppler signal will be continuously monitored on a computer (Moor instruments, VMS software V4.06) coupled with Moor instruments system (moorVMS-VASC). The thenar eminence will be used for the placement of the LDF probe (VP1T/7), consistently at the same place, before and post the occlusive reactive hyperaemia manoeuvre. The room temperature will be maintained at 22 degrees Celsius during forearm cutaneous blood flow measurements. The reactive hyperaemia will be produced by occluding the forearm blood flow with a pneumatic cuff inflated to a pressure of 50 mm Hg above the Systolic Blood Pressure for 3 minutes. The signal obtained during complete arterial occlusion will be taken as the biologic zero for cutaneous blood flow measurements before and during reactive hyperaemia. Resting flow will be taken as the average of a 6-minute stable LDF recording. The definition of the measurements taken are shown in figure 3 and the power spectral density (PSD) will be measured using the basic fast Fourier transform algorithm.

Cardio-Pulmonary Exercise Test (CPEX)

Exercise tolerance will be assessed by 6-minute walk test and CPEX, conducted in accordance with existing guidelines. For the walk test, participants will walk as far as possible in six minutes along a flat, obstacle free corridor, turning 180 degrees every 30m. For CPEX, participants will pedal a cycle ergometer at 70 rpm until volitional fatigue, using a ramp protocol. Breath-by-breath measurement of O₂ consumption, CO₂ production and ventilation will be used to determine key cardiorespiratory parameters including peak O₂ uptake (VO₂ peak), VO₂ at the anaerobic threshold (VO₂ AT) and ventilatory efficiency (VE/VO₂). Blood pressure, ECG and O₂ saturation will be continuously monitored. Criteria for a peak test will include respiratory exchange ratio (RER) >1.10.
Blinding

In order to reduce observer-bias the operator involved in the assessments of the primary outcome (pulse wave velocity) will be blinded to the comorbidities of the group of patients (A to E).

Primary Outcome

Our primary outcome will be a difference in arterial resistance between each of the five groups, as measured by aortic PWV. In addition, specific comparisons will be made between the control and hypertension groups as well as the control and HFpEF groups.

Secondary Outcomes

The secondary outcomes are to assess and compare endothelial function and cardiovascular performance in all groups as measured by the following:

- **Blood tests**: NTproBNP, high sensitivity Troponin T, Galectin-3
- **Urinalysis**: Albumin, Creatinine and Metabolite profiles (“metabolomics”), related to cardiovascular risk and insulin resistance
- **Transthoracic echocardiography (TTE)** indices of LV diastolic function, tissue Doppler imaging, strain rate imaging and measuring flow with pulsed-wave Doppler echocardiography interrogating the LV outflow tract.
- **Exercise tolerance**: 6-minute walk test and a Cardiopulmonary Exercise Test (CPEX)
End of study definition

The study will be closed at the last patient’s study visit.

Study funding and sponsor

The study has been funded by a research grant from the West Midlands Clinical Research Network, National Institute of Health Research, UK. The study is sponsored by the Research, Development & Innovation department of the University Hospitals Coventry & Warwickshire NHS Trust (RDI, UHCW), UK.

Study oversight

The Study will be monitored and overseen by the Study Management Group and the Research, Development and Innovation Department at UHCW.

Ethical approval and research governance

The study was approved by the regional research ethics committee (REC), West Midland and Black Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained from the RDI, UHCW NHS Trust. The study will be conducted in compliance with the principles of the
GCP guidelines and in accordance with all applicable regulatory guidance, including, but not limited to, the Research Governance Framework and the Health Research Authority, UK. Progress reports and a final report at the conclusion of the study will be submitted to the approving REC within the timelines defined by the committee.

**Dissemination and impact**

The hypothesis on which this study is based has been published. Error! Bookmark not defined. The results of the study will be presented at national and international conferences and released in appropriate media outlets, including social media. The results are expected to be published in peer-reviewed journals and presented in local, national and international medical scientific congresses and meetings. The study is anticipated to shed light on whether vascular stiffness is an important determinant of HFpEF which in turn could potentially encourage research for new therapeutic targets.

**Patient and public involvement**

Patient involvement has been essential to the design of and protocol of the study. Consultation has been obtained from patient and public involvement (PPI) representatives, which led to the tests being allowed to be done over two visits after screening. The non-invasive nature of the investigations has been particularly likened by the PPI representative. Furthermore, optional transport was provided to participants after their recommendation. Patients seen in the relevant outpatient department will be invited to participate in the study. On-going PPI input will occur during study steering committee. The results of the study will be disseminated to all the participants via post.
Competing interest

None declared
Table 1: Schedule of measures for every participant within the study.

| GROUP A ONLY: SEPARATE SCREENING VISIT PRIOR TO THE STUDY VISIT TO CHECK THAT THE |
PARTICIPANTS MEET THE ELIGIBILITY CRITERIA. FULL MEDICAL HISTORY, PHYSICAL EXAMINATION, BLOOD PRESSURE AND BLOOD TESTS (FBC, GLUCOSE, HBA1C, AND RENAL FUNCTION).

<table>
<thead>
<tr>
<th>TIME OF DAY</th>
<th>Procedures/Assessments*</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORNING</td>
<td>Eligibility check</td>
</tr>
<tr>
<td></td>
<td>Informed consent</td>
</tr>
<tr>
<td></td>
<td>Demographic data (DOB, sex, ethnicity, height and weight)</td>
</tr>
<tr>
<td></td>
<td>Relevant clinical history</td>
</tr>
<tr>
<td></td>
<td>Current medications</td>
</tr>
<tr>
<td></td>
<td>Blood pressure and Heart rate</td>
</tr>
<tr>
<td></td>
<td>Pulse Wave velocity (PWV) to measure arterial resistance</td>
</tr>
<tr>
<td></td>
<td>Laser Doppler to measure microvascular function</td>
</tr>
<tr>
<td></td>
<td>Blood tests: Full blood count, renal function and electrolytes, liver function tests, NT-proBNP, high-sensitive cardiac Troponin T (hs-cTnT). Samples will be frozen and stored for future analysis of vascular and other biomarkers e.g. Galectin-3</td>
</tr>
<tr>
<td></td>
<td>Urine test: Albumin and Creatinine. Samples will be frozen and stored for future analysis of metabolite profiles</td>
</tr>
<tr>
<td>LUNCH</td>
<td>Transthoracic echocardiography (TTE): tissue Doppler imaging and strain rate imaging</td>
</tr>
<tr>
<td>AFTERNOON</td>
<td>6-minute walk test</td>
</tr>
<tr>
<td></td>
<td>Cardiopulmonary Exercise Test (CPEX)</td>
</tr>
</tbody>
</table>

All assessments will be aimed to be completed in a single visit. However, a possible second visit can be arranged either at Atrium Health or University Hospitals Coventry and Warwickshire NHS Trust for completion of all assessments, if require.
Contributors

Contributors PB is the chief investigator for the study and DA leading on writing the protocol, ethics application and preparation of this manuscript. FC, MW, MM all contributed fully to study design. GM, NC, SM, SE and RP contributed from their respective discipline and authored the relevant section of the protocol and manuscript. All authors read and approved the final version of the manuscript.

13. References

2 https://www.nice.org.uk/guidance/cg108


7 Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions Heart Published Online First: 05 January 2018. doi: 10.1136/heartjnl-2016-310790.


10 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016

11 McMurray JJ, Adamopoulos S, Anker SD, et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847.


15 Balmain S, Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function, European Journal of Heart Failure 9 (2007) 865–871
Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


www.diabetes.org.uk

Balmain S, Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function, European Journal of Heart Failure 9 (2007) 865–871

Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016

22 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


25 www.diabetes.org.uk

26 Balmain S, Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function, European Journal of Heart Failure 9 (2007) 865–871

27 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016


29 Marechaux S, Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction, Journal of Cardiac Failure Vol. 22 No. 1 2016

